MassMutual Private Wealth & Trust FSB Purchases 17,681 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MassMutual Private Wealth & Trust FSB increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 26,389.6% during the 4th quarter, HoldingsChannel reports. The firm owned 17,748 shares of the specialty pharmaceutical company’s stock after buying an additional 17,681 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Jazz Pharmaceuticals were worth $2,186,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. CWA Asset Management Group LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the period. Centre Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $9,335,000. Pacer Advisors Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the period. Finally, Franklin Resources Inc. increased its position in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after purchasing an additional 48,708 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $121.18 on Tuesday. The firm has a market cap of $7.33 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 0.88 and a beta of 0.56. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company’s 50 day moving average is $122.66 and its 200 day moving average is $114.87.

Analyst Ratings Changes

A number of brokerages recently issued reports on JAZZ. Piper Sandler restated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, Robert W. Baird boosted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $177.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,253 shares of company stock valued at $1,001,434. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.